Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus GG + lactobacillus crispatus LBV88 + lactobacillus rhamnosus LBV96 + lactobacillus jensenii LBV116 + lactobacillus gasseri LBV150
- Development stage
- Unknown
- Lead developer
- Bifodan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This probiotic combination consists of five specific Lactobacillus strains: *Lactobacillus rhamnosus* GG (ATCC 53103), *Lactobacillus crispatus* LBV88 (DSM 22566), *Lactobacillus rhamnosus* LBV96 (DSM 22560), *Lactobacillus jensenii* LBV116 (DSM 22567), and *Lactobacillus gasseri* LBV150 (DSM 22583). Originally isolated from the vaginal microbiota of healthy pregnant women, these strains are formulated for oral administration to restore and maintain a healthy, lactobacilli-dominant vaginal environment. The combination works by colonizing the vaginal tract, where the bacteria produce lactic acid to lower pH, generate hydrogen peroxide and bacteriocins to inhibit pathogens, and competitively exclude harmful bacteria from adhering to the vaginal epithelium. It has been investigated in clinical trials for the treatment of vaginal dysbiosis and bacterial vaginosis, as well as for improving pregnancy outcomes such as reducing the risk of preterm birth and managing gestational diabetes mellitus.
- Other names
- EcoVag + LGGLGG + LBV88 + LBV96 + LBV116 + LBV150
Beyond the preview
Go deeper on lactobacillus rhamnosus GG + lactobacillus crispatus LBV88 + lactobacillus rhamnosus LBV96 + lactobacillus jensenii LBV116 + lactobacillus gasseri LBV150.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus GG + lactobacillus crispatus LBV88 + lactobacillus rhamnosus LBV96 + lactobacillus jensenii LBV116 + lactobacillus gasseri LBV150.